Is Assertio Therapeutics Inc (ASRT) overvalued? · rev $125.0M
Assertio Therapeutics Inc (ASRT) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Assertio Therapeutics Inc (ASRT) looks expensive on cached numbers — not a short thesis.
Latest reported ASRT revenue for 2024-12-31 was $125.0M. Net income was -$21.6M. Revenue was down 17.8% from 2023-12-31 to 2024-12-31. ASRT currently screens at market cap $151.5M.
ASRT currently screens at market cap $151.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ASRT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ASRT stock page for the full model, not this heading.
Not investment advice.